Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2025
Burden of eosinophilic esophagitis in adult and adolescent patients: results from a real-world analysis.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schoepfer Alain M, Olsen Stevie, Siddall James, McCann Eilish, Kamat Siddhesh, Borsos Kinga, Khodzhayev Angela, Radwan Amr, Pela Tiffany, Jacob-Nara Juby, Tilton Sarette T, Thomas Ryan B
Аннотация
BACKGROUND: Real-world data on the impact of eosinophilic esophagitis (EoE) in patients are limited. This study assessed clinical characteristics, healthcare resource utilization (HCRU), symptoms, comorbidities, and quality of life (QoL) of EoE patients.
METHODS: The multicountry cross-sectional survey, Adelphi EoE Disease Specific Programme™, collected physician and patient-reported data on clinical characteristics, HCRU, symptoms, comorbidities, and QOL of EoE patients with past/current proton pump inhibitor use and ongoing dysphagia-related symptoms (September to December 2020) at study entry.
RESULTS: Physicians provided clinical characteristics, symptom, comorbidity, and HCRU data for 412 patients (12-17 years: 8%; ≥18 years: 92%); and 161 of these patients (12-17 years: 6%; ≥18 years: 94%) provided symptom and QOL data. Of the 412 patients, 67% were male, with a mean (SD) age of 37.0 (15.3) years. Overall, 74% of patients were currently being treated with corticosteroids (12-17 years: 88%; ≥18 years: 73%); 25% of patients had a history of esophageal dilations (12-17 years: 19%; ≥18 years: 26%); and 30% of patients had EoE-related emergency room visit (12-17 years: 31%; ≥18 years: 30%) in the last year. Among the 161 patients, heartburn (69%) was the most commonly reported symptom; the greatest negative impacts on QOL were reported for dysphagia-related anxiety, social activities involving food, and maintaining friendships (EoE Impact Questionnaire scores [1-5, low to high impact]: 1.6-2.2 for both age groups).
CONCLUSION: EoE patients continued to experience disease burden despite receiving treatment, highlighting the high unmet need for effective disease management in this population.
METHODS: The multicountry cross-sectional survey, Adelphi EoE Disease Specific Programme™, collected physician and patient-reported data on clinical characteristics, HCRU, symptoms, comorbidities, and QOL of EoE patients with past/current proton pump inhibitor use and ongoing dysphagia-related symptoms (September to December 2020) at study entry.
RESULTS: Physicians provided clinical characteristics, symptom, comorbidity, and HCRU data for 412 patients (12-17 years: 8%; ≥18 years: 92%); and 161 of these patients (12-17 years: 6%; ≥18 years: 94%) provided symptom and QOL data. Of the 412 patients, 67% were male, with a mean (SD) age of 37.0 (15.3) years. Overall, 74% of patients were currently being treated with corticosteroids (12-17 years: 88%; ≥18 years: 73%); 25% of patients had a history of esophageal dilations (12-17 years: 19%; ≥18 years: 26%); and 30% of patients had EoE-related emergency room visit (12-17 years: 31%; ≥18 years: 30%) in the last year. Among the 161 patients, heartburn (69%) was the most commonly reported symptom; the greatest negative impacts on QOL were reported for dysphagia-related anxiety, social activities involving food, and maintaining friendships (EoE Impact Questionnaire scores [1-5, low to high impact]: 1.6-2.2 for both age groups).
CONCLUSION: EoE patients continued to experience disease burden despite receiving treatment, highlighting the high unmet need for effective disease management in this population.